SAN DIEGO, Calif., Nov. 20, 2018 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members
of its senior management team will participate in two upcoming
investor conferences:
- Evercore ISI HealthCONx Conference – Presenting on Wednesday, November 28, at 4:15PM EST in
Boston
- Citi Global Healthcare Conference – Hosting investor meetings
on Wednesday, December 5 and Thursday,
December 6, in New York City
A live audio webcast of the presentation will be available under
the investor relations section of Arena's website at
www.arenapharm.com. A replay of the presentation will be available
for 30 days following the event.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
driven to deliver novel, transformational medicines with optimized
pharmacology and pharmacokinetics to patients globally. Arena's
proprietary pipeline includes multiple potentially first- or
best-in-class assets with broad clinical utility. Etrasimod
(APD334), with potential utility in a broad range of immune and
inflammatory conditions, is being evaluated in later-stage clinical
programs in ulcerative colitis (UC) and Crohn's disease, as well as
in programs for primary biliary cholangitis (PBC) and atopic
dermatitis. Ralinepag (APD811) is being evaluated in a Phase 3
program for pulmonary arterial hypertension (PAH). Arena is also
evaluating olorinab (APD371) in a Phase 2 program for
gastrointestinal pain. Arena continues to assess other earlier
research and development stage drug candidates, including APD418
for decompensated heart failure.
In addition, Arena has several partnerships including with
Everest Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries),
Axovant Sciences GmbH (nelotanserin - Phase 2), Boehringer
Ingelheim International GmbH (undisclosed target - preclinical),
Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai
Co., Ltd. and Eisai Inc. (BELVIQ® - marketed
product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
accompanied by words such as "will," "driven to," "potentially,"
"potential," or words of similar meaning, or they may be identified
by the fact that they do not relate strictly to historical or
current facts. Such forward-looking statements include, without
limitation, statements about Arena's participation in the upcoming
investor conferences and Arena's drive, focus, goals, strategy,
clinical and research and development programs, and collaborations.
For such statements, Arena claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Arena's expectations. Factors that could
cause actual results to differ materially from the forward-looking
statements include that clinical and preclinical programs may not
proceed at the time or in the manner expected or at all, as well as
those factors disclosed in Arena's filings with the Securities
and Exchange Commission (SEC), including but not limited to
our Quarterly Report on Form 10-Q for the quarter
ended September 30, 2018, which was filed with
the SEC on November 8, 2018. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate
Contact:
Kevin R.
Lind
Arena
Pharmaceuticals, Inc.
Executive Vice
President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
|
|
Media
Contact:
Matt Middleman,
M.D.
LifeSci Public
Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-participate-in-upcoming-investor-conferences-300753358.html
SOURCE Arena Pharmaceuticals, Inc.